EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

Reyon Pharmaceutical Co Ltd (102460) fair value: what the stock is really worth

As of Oct 2, 2026: fair value of Reyon Pharmaceutical Co Ltd KRW 7,890, price KRW 10,120, upside -22.0%, quality 34 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Fair value above price? No
  2. Good quality? No
  3. Add to watchlist

Healthcare · KR · ISIN KR7102460003

RP Thin data Oct 2, 2026

Reyon Pharmaceutical Co Ltd

102460 · KO

Weak valuationQuality is weak on top of the rich price.

Low debt
Mixed Growth (revenue 5y +2.3 %/yr in KRW)
Fair value 7,890 KRW · Overvalued (−22.0%)
Quality 34/100
Loss-making · -23.9% net margin (TTM)
Negative free cash flow
Trails peers (0/10)
Narrow moat 9/100
Thin data
Watch Reyon Pharmaceutical Co Ltd for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

70,413 KRW 9,770 KRW Fair Value 7,890 KRW May 2021 Oct 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Oct 2, 2026.

How to read this chart

60‑month range 9,770 KRW – 70,413 KRW · fair‑value band 5,888 KRW – 11,776 KRW · the 10,120 KRW price screens above the 7,890 KRW fair value. Dashed = 300-day average. As of Oct 2, 2026.

Follow Reyon Pharmaceutical Co in your weekly email

Every Wednesday you see whether Reyon Pharmaceutical Co is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

REYON Pharmaceutical Co., Ltd. manufactures and sells medicines.

Show more

REYON Pharmaceutical Co., Ltd. manufactures and sells medicines. The company offers its products under the areas of adrenal corticosteroides; angiotensin II receptor antagonists; antibiotics; anticholinergics; antiemetic; antihypertensives; anti-inflammatory enzymes; antilipidemic, antirheumatic, and oral hypoglycemic agents; anti-peptic ulcer; antispasmodics; benign prostatic hypertrophy; cough and cold remedies; cardiac stimulant; genitourinary smooth muscle relaxants; hemostatics; immunosuppressants; rheumatoid arthritis; local anesthetics; migraine drugs; miscellaneous cardiovascular system drugs; neuromuscular disorder related drugs; nootropics and neurotonics; NSAIDs; respiratory stimulants; skeletal muscle relaxants; and vasodilators. It also develops VM202RY, a vascular neurological disease, etc. gene therapy drug, which is in Phase II clinical trial to treat coronary artery disease, chronic non-healing diabetic/ischemic ulcers, diabetic neuropathy, and amyotrophic lateral sclerosis; VM206RY, anti-cancer gene therapy, which is under Phase I clinical trials for treatment of breast cancer; RY103 [NS101], therapeutics antibody for Alzheimer; and RY104, a gene therapy to treat age-related macular degeneration, as well as BIO-101, a HBV gene vaccine, which is in preclinical studies for hepatitis B; RY105, gene therapy to treat liver fibrosis; GB102, for treatment of chronic kidney and coronary artery disease; RY110 which is an iPSC-derived NK cell therapy for solid tumors; RY108, an antifungal drug which is under preclinical study. In addition, the company engages in the research of RY106/RY107, a mRNA-based virus vaccine and gene therapy for anti-virus and rare genetic diseases; and RY109 which is a pDNA-based cancer vaccine for treatment of Ovarian cancer. REYON Pharmaceutical Co., Ltd. was founded in 1955 and is headquartered in Seoul, South Korea.

Stock analysis

Reyon Pharmaceutical Co Ltd (102460) currently trades at 10,120 KRW, while our model-based Fair Value estimate is 7,890 KRW, 22.0% below the price, so the stock looks overvalued today.

Show more

Valuation

How firm this estimate is: it rests on 2 models at a data quality of 95/100, which puts the evidence level at low.

Scenario range: 5,888 KRW (bear) to 11,776 KRW (bull), the price of 10,120 KRW sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 34/100 (below-average quality), in the Healthcare sector.

Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.

Reyon Pharmaceutical Co Ltd reported revenue of 146B KRW in FY2025 versus 143B KRW in FY2021, a compound +0.5%/yr. Reported net income was −29.6B KRW in FY2025.

Key figures

Market cap 186B KRW (≈ $138M) · P/S ratio 1.29 · Dividend yield 1.5% · Net margin −20.3% · Return on equity −15.9% · Return on assets (EBIT) −0.7% · Operating margin −19.6% · Revenue (TTM) 143B KRW.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 28 out of 100 (medium confidence).

What moves the price

The share trades about 19% below its 52-week high and 4% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −19% fair-value upside, at −22%, 102460 screens richer than that median.

Fair Value models

Bear 5,888 KRW Fair Value 7,890 KRW Bull 11,776 KRW
Price 10,120 KRW · Upside -22.0%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
NCAV (Graham) 6,005 KRW 8,047 KRW 12,010 KRW 54
All 1 models by family
Asset-Based
NCAV (Graham) 6,005 KRW 8,047 KRW 12,010 KRW 54

Open the full fair value analysis →

Notify me when 102460 reaches fair value

Put 102460 on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 34/100

Of which business quality 34 · Market factors (momentum, volatility) 43

Profitability 6
Margins and returns on capital today
Quality Growth 34
Are margins and returns improving?
Cashflow 6
Earnings quality: real cash, not paper profit
Fin. Strength 31
Balance sheet, leverage, solvency risk
Investment 94
Disciplined investing over empire-building
Low Volatility 77
Calm price path (market factor)
Momentum 36
Price trend over the last 3–12 months (market factor)
52W Momentum 15
Distance to the 52-week high (market factor)
Net Issuance 76
Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 2/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
−1.6%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−1.8%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+2.3%
Start year 2020 (pandemic)
Revenue growth 17 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+4.2%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
2.7% (2020) → −21.0% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

102460 screens overvalued: fair value 22% below the price. Compare with Merck KGaA →

Compare Reyon Pharmaceutical Co Ltd with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 602 stocks

Beats the industry median on 0/9 measures
Overall it trails its industry peers.
Valuation
Quality Score 34 · Bottom 25%
Fair Value upside −22.0% · Below median
Profitability
Return on assets −4.1% · Bottom 25%
Net margin (TTM) −23.9% · Bottom 25%
Operating margin (TTM) −19.6% · Bottom 25%
Growth and dividend
Revenue growth −4.9% · Below median
Dividend yield (TTM) 1.5% · Below median
Balance sheet
Debt / equity 0.45× · Highest 25%

Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper

EV/EBITDA 54.5× · Priciest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)4 · sector 16
FUTURE (revenue growth)0 · sector 24
PAST (return on equity)0 · sector 26
HEALTH (low debt)78 · sector 96
DIVIDEND (yield)30 · sector 31

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value
Merck KGaA MRK €134.45 €108.94 −19%
Takeda Pharmaceutical Company TAK $17.86 $11.35 −36%
Teva Pharmaceutical Industries Limited TEVA $39.31 $20.88 −47%
Sun Pharmaceutical Industries Limited SUNPHARMA ₹1,852 ₹1,979 +7%
Galderma Group GALD CHF 163.00 CHF 110.32 −32%
Jiangsu Hengrui Pharmaceuticals Co 600276 ¥44.86 ¥49.35 +10%
Haleon plc HLN $9.26 $8.49 −8%
Sandoz Group SDZ CHF 71.16 CHF 40.32 −43%
Zoetis Inc ZTS $70.30 $110.50 +57%
Divi's Laboratories Limited DIVISLAB ₹9,620 ₹1,871 −81%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
DCF CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorFama-French ModelIntrinsic Value
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Reyon Pharmaceutical Co Ltd · Fair Value
7,890 KRW −22%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "Reyon Pharmaceutical Co Ltd Fair Value". https://www.fairvalue-calculator.com/stock/102460

Frequently asked questions

Is Reyon Pharmaceutical Co Ltd (102460) overvalued or undervalued?
As of Oct 2, 2026, our model estimates a fair value of 7,890 KRW versus a price of 10,120 KRW, about −22% upside (overvalued).
What is the fair value of 102460?
Our model-based fair value for Reyon Pharmaceutical Co Ltd is 7,890 KRW (as of Oct 2, 2026), built from audited fundamentals. The current price: 10,120 KRW.
What is the quality score of 102460?
Reyon Pharmaceutical Co Ltd has a Quality Score of 34/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Reyon Pharmaceutical Co Ltd (102460)?
Our model-based price target is the fair value of 7,890 KRW (as of Oct 2, 2026) from 1 valuation models. Cautious scenario 5,888 KRW, optimistic scenario 11,776 KRW. It is a calculation from audited fundamentals, not an analyst target.
What is the Reyon Pharmaceutical Co Ltd stock forecast for 2026?
Our models put fair value at 7,890 KRW, about −22% upside versus a price of 10,120 KRW (overvalued). Cautious scenario 5,888 KRW, optimistic scenario 11,776 KRW. The calculation is refreshed regularly with new filings.
What is the revenue of Reyon Pharmaceutical Co Ltd (102460)?
Reyon Pharmaceutical Co Ltd reported trailing-twelve-month revenue of about 143B KRW (latest available figure, as of Oct 2, 2026).
Does Reyon Pharmaceutical Co Ltd pay a dividend?
Reyon Pharmaceutical Co Ltd currently shows a dividend yield of about 1.48% relative to its recent price (as of Oct 2, 2026).
What is the intrinsic value of Reyon Pharmaceutical Co Ltd (102460)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Reyon Pharmaceutical Co Ltd it is 7,890 KRW per share (as of Oct 2, 2026), against a price of 10,120 KRW. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is Reyon Pharmaceutical Co Ltd stock overvalued or undervalued in 2026?
As of Oct 2, 2026, 102460 trades above its calculated fair value: price 10,120 KRW, fair value 7,890 KRW, a gap of about −22% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 102460?
No. The price is what the market pays today (10,120 KRW); the fair value is what the company's own numbers justify (7,890 KRW). For Reyon Pharmaceutical Co Ltd the two are 2,230 KRW per share apart. That gap is exactly why we show both numbers side by side.
How much is Reyon Pharmaceutical Co Ltd worth?
The market values Reyon Pharmaceutical Co Ltd at about 186B KRW (market capitalisation, as of Oct 2, 2026). Per share that is 10,120 KRW; our models calculate a fair value of 7,890 KRW per share.
What do the bullish and bearish scenarios say about 102460?
Our models span a range for Reyon Pharmaceutical Co Ltd: cautious scenario 5,888 KRW, base 7,890 KRW, optimistic 11,776 KRW per share (as of Oct 2, 2026, price 10,120 KRW). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Reyon Pharmaceutical Co Ltd (102460)?
Balance-sheet figures for Reyon Pharmaceutical Co Ltd (as of Oct 2, 2026): return on equity −15.9%, debt of 0.45 per unit of equity. They feed the Quality Score of 34/100, which measures business quality independently of the share price.
How far is 102460 from its 52-week high?
Reyon Pharmaceutical Co Ltd trades at 10,120 KRW, about 19% below its 52-week high of 12,570 KRW and 4% above the low of 9,770 KRW (as of Oct 2, 2026). Distance from the high says nothing about value: that is what the fair value of 7,890 KRW is for.
Which stocks are comparable to Reyon Pharmaceutical Co Ltd?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Teva Pharmaceutical Industries Limited, Sun Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Reyon Pharmaceutical Co Ltd stock attractive at the current price?
The data as of Oct 2, 2026: price 10,120 KRW, calculated fair value 7,890 KRW (−22%), Quality Score 34/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 102460 calculated?
We run Reyon Pharmaceutical Co Ltd through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 7,890 KRW, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 15.0 % above its aggregate fair value. Reyon Pharmaceutical Co Ltd itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Reyon Pharmaceutical Co Ltd (102460)?
The closing price on Oct 2, 2026 was 10,120 KRW. Our model-based fair value is 7,890 KRW, about −22% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Reyon Pharmaceutical Co Ltd right now?
Weak quality (34/100) and above fair value at the same time, the margin of safety is missing on both counts. A fairly wide model range (5,888 KRW to 11,776 KRW) leaves room in how you read the outcome. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.

Key figures of Reyon Pharmaceutical Co Ltd

How large is the market capitalisation of Reyon Pharmaceutical Co Ltd (102460)?
The market capitalisation of Reyon Pharmaceutical Co Ltd is 186B KRW (≈ $138M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Reyon Pharmaceutical Co Ltd (102460)?
The price-to-sales ratio of Reyon Pharmaceutical Co Ltd is 1.29 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What is the dividend yield of Reyon Pharmaceutical Co Ltd (102460)?
The dividend yield of Reyon Pharmaceutical Co Ltd is 1.5%. Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Reyon Pharmaceutical Co Ltd (102460)?
The net margin of Reyon Pharmaceutical Co Ltd is −20.3% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Reyon Pharmaceutical Co Ltd (102460)?
The return on equity (ROE) of Reyon Pharmaceutical Co Ltd is −15.9% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Reyon Pharmaceutical Co Ltd (102460)?
On an EBIT basis the return on assets of Reyon Pharmaceutical Co Ltd is −0.7% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Reyon Pharmaceutical Co Ltd (102460)?
The operating margin of Reyon Pharmaceutical Co Ltd is −19.6% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Reyon Pharmaceutical Co Ltd (102460)?
Revenue at Reyon Pharmaceutical Co Ltd is growing −4.9% versus a year earlier (3y avg −1.8%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Reyon Pharmaceutical Co Ltd (102460)?
Earnings per share at Reyon Pharmaceutical Co Ltd are growing −21.5% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Reyon Pharmaceutical Co Ltd (102460) generate?
The free cash flow of Reyon Pharmaceutical Co Ltd is −6.5B KRW (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Reyon Pharmaceutical Co Ltd (102460) carry?
The net debt of Reyon Pharmaceutical Co Ltd is 208B KRW (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Reyon Pharmaceutical Co Ltd in the live analysis

One click puts Reyon Pharmaceutical Co Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.